EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Trough Concentrations of Linezolid and Its Metabolites in Relation to Renal Function and Toxicity

Meng Liu, Haoxin Fu, Xiaohai Chen, Zhenwei Yu, Ren-Ai Xu, Yingying Wang

Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-11

DOI: 10.2147/dddt.s607396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Meng Liu und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Linezolid therapy may be complicated by hematologic toxicity and lactic acidosis. Its major metabolites, PNU-142300 and PNU-142586, can accumulate with impaired renal function, but their contribution to adverse outcomes remains uncertain. Renal function and baseline laboratory abnormalities may confound concentration-outcome associations, highlighting the need to assess whether metabolite measurements provide additional information beyond routinely available clinical indicators.

Objective

To assess the associations of linezolid, PNU-142300, and PNU-142586 trough concentrations ( C min ) with renal function and adverse outcomes during treatment, and their exploratory discriminative performance.

Methods

A retrospective observational study was conducted in patients who had received linezolid and in whom C min of linezolid and its metabolites (PNU-142300 and PNU-142586) was available. An ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was used to quantify these compounds in human serum. Linear regression was performed to evaluate the association between C min of linezolid and its metabolites. The correlation of linezolid, PNU-142300, and PNU-142586 with eCrCl were analyzed by Spearman rank correlation coefficient. C min of linezolid and its metabolites were compared with different linezolid-related toxicity groups. The receiver operating characteristic (ROC) curve was used to analyze the associative values of linezolid and its metabolites for anemia, thrombocytopenia, and lactic acidosis, and the area under the curve (AUC) was calculated.

Results

Thrombocytopenia, anemia, and lactic acidosis occurred in 44 (17.5%), 53 (21.0%), and 56 (22.2%) patients, respectively. All analytes were inversely correlated with eCrCl (linezolid, r =− 0.423; PNU-142300, r =− 0.715; PNU-142586, r =− 0.683; all P < 0.001). After adjustment, no analyte was significantly associated with thrombocytopenia, and neither metabolite was significantly associated with anemia. Linezolid showed an unexpected inverse association with anemia (adjusted OR, 0.934; P =0.030). Higher linezolid, PNU-142300, and PNU-142586 concentrations were associated with lactic acidosis (adjusted ORs, 1.073, 1.027, and 1.031; P =0.004, 0.014, and 0.047, respectively). Individual-analyte AUCs ranged from 0.641 to 0.680. Adding each analyte to baseline lactate, eCrCl, and age increased the apparent AUC from 0.675 to 0.707– 0.720, without statistically significant improvement.

Conclusion

Concentration measurements should complement baseline and serial laboratory assessments and renal-function evaluation. The clinical value of additional metabolite monitoring remains unestablished. Prospective validation is required before routine metabolite-specific TDM can be recommended. Keywords: linezolid, metabolites, UPLC-MS/MS, toxicity, TDM

Zitieren

APA

Liu, M., Fu, H., Chen, X., Yu, Z., Xu, R., & Wang, Y. (2026). Trough Concentrations of Linezolid and Its Metabolites in Relation to Renal Function and Toxicity. Drug Design, Development and Therapy, Volume 20, 1-11. https://doi.org/10.2147/dddt.s607396

Vancouver

Liu M, Fu H, Chen X, Yu Z, Xu R, Wang Y. Trough Concentrations of Linezolid and Its Metabolites in Relation to Renal Function and Toxicity. Drug Design, Development and Therapy. 2026;Volume 20:1-11. doi:10.2147/dddt.s607396

BibTeX
@article{Liu2026,
  author = {Liu, Meng and Fu, Haoxin and Chen, Xiaohai and Yu, Zhenwei and Xu, Ren-Ai and Wang, Yingying},
  title = {Trough Concentrations of Linezolid and Its Metabolites in Relation to Renal Function and Toxicity},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--11},
  doi = {10.2147/dddt.s607396}
}
Kostenlos starten →